Advertisement
To access the conference call by telephone, dial 416-644-3422 or1-800-731-5319. Please connect approximately ten minutes prior to thebeginning of the call to ensure participation. The conference call will bearchived for replay until May 19, 2008 at midnight. To access the archivedconference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservationnumber 21270216 followed by the number sign.
Advertisement
A live audio webcast of the conference call will be available atwww.novadaq.com. Please connect at least ten minutes prior to the conferencecall to ensure adequate time for any software download that may be required tojoin the webcast. The webcast will be archived at the above website for 365days.
About Novadaq Technologies
Novadaq Technologies Inc. commercializes real-time imaging and imageguidance systems for use in the operating room. With one set of proprietarycore technologies, Novadaq's products have multiple applications. Novadaq'sSPY(R) System enables cardiac surgeons to diagnose intra-operatively byvisually assessing coronary vasculature and bypass graft functionality duringthe course of heart bypass surgery. The SPY System is also indicated for useduring other surgeries, such as cardiovascular, plastic, reconstructive, organtransplant and urological procedures. SPY can be used to visualize bloodvessels, tumors, tumor margins and the lymphatic system. Novadaq introducedPINPOINT(TM), its first minimally invasive imaging system for autofluorescencein October 2007. PINPOINT allows surgeons to differentiate between healthy andcancerous tissue in the lung and other hollow organs. Further expanding itsportfolio of minimally invasive products, Novadaq is developing SPYscope whichcombines the typical features of a standard endoscope with the additionalcapabilities of SPY imaging. Novadaq is the exclusive United Statesdistributor of PLC Medical's CO2 HEART LASER System, used in the same cardiacprocedures as the SPY System. Novadaq also offers the OPTTX(R) System, whichleverages the company's core imaging technology and is designed for thediagnosis, evaluation and treatment of wet Age-related Macular Degeneration(AMD). For more information, please visit the company's website atwww.novadaq.com.
Forward looking Statements
Certain statements included in this press release may be consideredforward-looking. Such statements involve known and unknown risks,uncertainties and other factors that may cause actual results, performance orachievements to be materially different from those implied by such statements,and therefore these statements should not be read as guarantees of futureperformance or results. All forward-looking statements are based on Novadaq'scurrent beliefs as well as assumptions made by and information currentlyavailable to Novadaq and relate to, among other things, results of futureclinical tests of PINPOINT and the SPY System, anticipated financialperformance, business prospects, strategies, regulatory developments, marketacceptance and future commitments. Readers are cautioned not to place unduereliance on these forward-looking statements, which speak only as of the dateof this press release. Due to risks and uncertainties, including the risks anduncertainties identified by Novadaq in its public securities filings actualevents may differ materially from current expectations. Novadaq disclaims anyintention or obligation to update or revise any forward-looking statements,whether as a result of new information, future events or otherwise.
SOURCE Novadaq Technologies Inc.
